BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma

This study is ongoing, but not recruiting participants.
Information provided by MedImmune LLC

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:

1		Conditions listed in this trial
			Leukemia
			Lymphoma
2		Additional conditions recognized in this trial
			Leukemia, B-Cell
			Leukemia, Lymphocytic, Chronic, B-Cell
			Leukemia, Lymphoid
			Leukemia, Prolymphocytic
			Lymphoma, Non-Hodgkin
3		More general conditions related to this trial
			Immune System Diseases
			Immunoproliferative Disorders
			Lymphatic Diseases
			Lymphoproliferative Disorders
			Neoplasms
			Neoplasms by Histologic Type
4		Interventions listed in this trial
			BL22 immunotoxin
			antibody-drug conjugate therapy
			immunotoxin therapy
5		Additional drug interventions recognized in this trial
			Immunotoxins
6		More general drug interventions related to this trial
			Immunologic Factors
			Pharmacologic Actions
			Physiological Effects of Drugs
7		Sponsors listed in this trial
			MedImmune LLC